A new treatment, retatrutide, has shown promising results in managing type 2 diabetes, with up to 40% of patients achieving normal HbA1c levels. Other recent developments in diabetes treatment include the launch of a weekly basal insulin and positive results from a phase III trial of a GLP-3 drug. The effectiveness and tolerability of various medications, including GLP-1/glucagon agonists and oral small-molecule treatments, are being studied and compared in different trials and real-world data analyses.